Recursion highlighted progress on 2 drug programs and plans to advance them. The report gives no trial findings or financial figures, so it does not show a clear change in the company's prospects.
The report names progress on 2 drug programs and plans to advance them. It gives no trial findings or financial figures, so it does not show a clear change in the company's prospects.
Follow Recursion Pharmaceuticals, Inc. (RXRX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RXRX